Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
Novo Nordisk stock is having a rough week after that Hims & Hers Super Bowl ad
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
pharmaphorum16h
Novo Nordisk splashes out as oral semaglutide starts phase III
Novo Nordisk's semaglutide ... One of these, at Clayton in North Carolina, will focus on producing active pharmaceutical ingredients (APIs) for isemaglutide and other diabetes drugs, while ...
Barron's17h
Novo Nordisk A/S ADR
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Indiatimes19h
Natco Pharma Share Price
Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 17,464.11 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments ...
Indiatimes19h
Mankind Pharma Share Price
Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 1,03,189.17 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...